Molecular Templates Inc
NASDAQ:MTEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Molecular Templates Inc
NASDAQ:MTEM
|
US |
|
Baylin Technologies Inc
TSX:BYL
|
CA |
|
New Talisman Gold Mines Ltd
NZX:NTL
|
NZ |
|
A
|
Aptamer Group PLC
LSE:APTA
|
UK |
|
D
|
Daewoong Co Ltd
KRX:003090
|
KR |
|
Andon Health Co Ltd
SZSE:002432
|
CN |
|
Q32 Bio Inc
LSE:0T6G
|
US |
|
J
|
Jiangsu Yoke Technology Co Ltd
SZSE:002409
|
CN |
|
S
|
Starhedge SA
WSE:SHG
|
PL |
|
F
|
First Helium Inc
XTSX:HELI
|
CA |
Molecular Templates Inc
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 261 full-time employees. The company went IPO on 2005-02-04. The firm utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The firm is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 261 full-time employees. The company went IPO on 2005-02-04. The firm utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The firm is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
